Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIZZ
- 02 Dec 2013 Status changed from active, no longer recruiting to completed according to results published in Journal of Clinical Oncology.
- 15 Dec 2011 Bayer as trial company, lead trial centre and additional location (France) added as reported by ClinicalTrials.gov.
- 15 Dec 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).